Frontiers in Oncology (Mar 2021)
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study
- Ling Xu,
- Yinhua Liu,
- Zhimin Fan,
- Zefei Jiang,
- Yunjiang Liu,
- Rui Ling,
- Jianguo Zhang,
- Zhigang Yu,
- Feng Jin,
- Chuan Wang,
- Shude Cui,
- Shu Wang,
- Dahua Mao,
- Bing Han,
- Tao Wang,
- Geng Zhang,
- Ting Wang,
- Baoliang Guo,
- Lixiang Yu,
- Yingying Xu,
- Fangmeng Fu,
- Zhenzhen Liu,
- Siyuan Wang,
- Ke Luo,
- Qian Xiang,
- Zhuo Zhang,
- Qianxin Liu,
- Bin Zhou,
- Zhaorui Liu,
- Chao Ma,
- Weiwei Tong,
- Jie Mao,
- Xuening Duan,
- Yimin Cui
Affiliations
- Ling Xu
- Breast Disease Center, Peking University First Hospital, Beijing, China
- Yinhua Liu
- Breast Disease Center, Peking University First Hospital, Beijing, China
- Zhimin Fan
- Department of Breast Surgery, First Hospital of Jilin University, Changchun, China
- Zefei Jiang
- Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China
- Yunjiang Liu
- Hebei Breast Cancer Center, The 4th Hospital of Hebei Medical University, Shijiazhuang, China
- Rui Ling
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force (Military) Medical University, Xi’an, China
- Jianguo Zhang
- Breast Disease Department, Second Affiliated Hospital of Harbin Medical University, Harbin, China
- Zhigang Yu
- Department of Breast Surgery, Second Hospital of Shandong University, Jinan, China
- Feng Jin
- Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China
- Chuan Wang
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
- Shude Cui
- 0Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China
- Shu Wang
- 1Breast Center, Peking University People’s Hospital, Beijing, China
- Dahua Mao
- 2Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- Bing Han
- Department of Breast Surgery, First Hospital of Jilin University, Changchun, China
- Tao Wang
- Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China
- Geng Zhang
- Hebei Breast Cancer Center, The 4th Hospital of Hebei Medical University, Shijiazhuang, China
- Ting Wang
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force (Military) Medical University, Xi’an, China
- Baoliang Guo
- Breast Disease Department, Second Affiliated Hospital of Harbin Medical University, Harbin, China
- Lixiang Yu
- Department of Breast Surgery, Second Hospital of Shandong University, Jinan, China
- Yingying Xu
- Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China
- Fangmeng Fu
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
- Zhenzhen Liu
- 0Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China
- Siyuan Wang
- 1Breast Center, Peking University People’s Hospital, Beijing, China
- Ke Luo
- 2Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- Qian Xiang
- 3Department of Pharmacy, Peking University First Hospital, Beijing, China
- Zhuo Zhang
- 3Department of Pharmacy, Peking University First Hospital, Beijing, China
- Qianxin Liu
- 3Department of Pharmacy, Peking University First Hospital, Beijing, China
- Bin Zhou
- Breast Disease Center, Peking University First Hospital, Beijing, China
- Zhaorui Liu
- 4Institute of Mental Health, Peking University, Beijing, China
- Chao Ma
- 4Institute of Mental Health, Peking University, Beijing, China
- Weiwei Tong
- 5Gennlife (Beijing) Technology Co., Ltd, Beijing, China
- Jie Mao
- 5Gennlife (Beijing) Technology Co., Ltd, Beijing, China
- Xuening Duan
- Breast Disease Center, Peking University First Hospital, Beijing, China
- Yimin Cui
- 3Department of Pharmacy, Peking University First Hospital, Beijing, China
- DOI
- https://doi.org/10.3389/fonc.2021.606477
- Journal volume & issue
-
Vol. 11
Abstract
This study was to assess the prognosis stratification of the clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease, the nuclear grade 3 tumor pathology (CPS + EG), Neo-Bioscore, and a modified Neo-Bioscore system in breast cancer patients after preoperative systemic therapy (PST). A retrospective multicenter cohort study was conducted from 12 participating hospitals’ databases from 2006 to 2015. Five-year disease free survival (DFS), disease specific survival (DSS), and overall survival (OS) were calculated using Kaplan–Meier Method. Area under the curve (AUC) of the three staging systems was compared. Wald test and maximum likelihood estimates in Cox proportional hazards model were used for multivariate analysis. A total of 1,077 patients were enrolled. The CPS + EG, Neo-Bioscore, and modified Neo-Bioscore could all stratify the DFS, DSS, and OS (all P < 0.001). While in the same stratum of Neo-Bioscore scores 2 and 3, the HER2-positive patients without trastuzumab therapy had much poorer DSS (P = 0.013 and P values < 0.01, respectively) as compared to HER2-positive patients with trastuzumab therapy and HER2-negative patients. Only the modified Neo-Bioscore had a significantly higher stratification of 5-year DSS than PS (AUC 0.79 vs. 0.65, P = 0.03). So, the modified Neo-Bioscore could circumvent the limitation of CPS + EG or Neo-Bioscore.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT03437837.
Keywords
